MedPath

Training in the Fasted State, Glucose Metabolism and Energy Balance

Not Applicable
Completed
Conditions
Glucose Metabolism Disorders
Interventions
Behavioral: Exercise
Behavioral: Maintain habitual habits
Behavioral: Breakfast
Registration Number
NCT02744183
Lead Sponsor
University of Bath
Brief Summary

In healthy individuals, the body responds to glucose (sugar) ingestion by reducing the amount released from the liver. At the same time, skeletal muscles increase the rate at which they remove the glucose from the bloodstream, via the actions of the hormone insulin. This ensures that blood glucose levels remain in a controlled range. However, in developed countries, diseases such as metabolic syndrome and type 2 diabetes are becoming prevalent, due to dietary modifications and a reduction in physical activity. As one of the prominent barriers to regular physical activity is a lack of time, finding ways to maximize the health benefits of exercise is a priority for researchers.

The investigators want to understand potential differences in the effects of six weeks of aerobic training, with the exercise performed either after breakfast or after a prolonged fast. Specifically, this research aims to investigate whether there is a difference in the change in processes implicated in glucose regulation and secondly, in subsequent eating and physical activity behaviors. By investigating these changes this work will explore how exercise and nutrition can be optimized to benefit health and weight loss.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
30
Inclusion Criteria
  • Male
  • Aged 18-49
  • Body mass index (BMI) > 25 kg/m2
  • Weight stable for > 6 months
  • Not currently engaging in any form of structured exercise
  • Be able and willing to give informed oral and written consent
  • Complete and meet the defined criteria of pre-study questionnaires and screen
Read More
Exclusion Criteria
  • Have a history of metabolic, cardio-pulmonary or musculoskeletal disease
  • Have plans to change diet and/or physical activity outside of the intervention
  • Taking regular medication or food supplements from which it is not possible to refrain and which are known to influence any of the outcome measures.
  • Failure to refrain from alcohol and/or caffeine containing drinks or strenuous exercise one day before or during the trial days
  • Smokers
  • Any reported condition or behavior deemed to pose a risk to the participant or introduce bias into the experiment
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Fasted ExerciseExercise6 weeks of moderate intensity exercise with breakfast omission
Fed ExerciseBreakfast6 weeks of moderate intensity exercise with breakfast consumption
Control GroupMaintain habitual habitsMaintain habitual habits
Fed ExerciseExercise6 weeks of moderate intensity exercise with breakfast consumption
Primary Outcome Measures
NameTimeMethod
Postprandial plasma glucose concentrations120 mins - (change after 6 weeks)

Response to oral glucose tolerance test (area under the curve)

Postprandial insulin concentrations120 mins - (change after 6 weeks)

Response to oral glucose tolerance test (area under the curve)

Secondary Outcome Measures
NameTimeMethod
Oral Glucose Insulin Sensitivity Index120 mins - (change after 6 weeks)

Response to oral glucose tolerance test

Habitual energy expenditureChange after 6 weeks

Assessed via an Actiheart monitor, completed at baseline and during the last week of the intervention

Waist and hip circumference (cm)Change after 6 weeks
Cardiorespiratory fitness (VO2max)Change after 6 weeks
Habitual energy intakeChange after 6 weeks

Assessed via a food diary, completed at baseline and during the last week of the intervention

Body mass (kg)Change after 6 weeks
Fasting plasma glucose concentrationBasal Concentrations - (change after 6 weeks)

Fasting plasma glucose concentration (mmol/L)

Maximal rate of whole-body lipid oxidation (g/min)Change after 6 weeks

During an incremental exercise test

Fasting plasma HDL cholesterol concentrationsBasal Concentrations - (change after 6 weeks)

Fasting plasma HDL cholesterol concentrations (mmol/L)

Fasting plasma LDL cholesterol concentrationsBasal Concentrations - (change after 6 weeks)

Fasting plasma LDL cholesterol concentrations (mmol/L)

Postprandial plasma glycerol concentrationsChange after 6 weeks

Response to oral glucose tolerance test (total and incremental area under the curve)

Fasting plasma insulin concentrationBasal Concentrations - (change after 6 weeks)

Fasting plasma insulin concentration (pmol/L)

Postprandial non-esterified fatty acid concentrations120 mins - (change after 6 weeks)

Response to oral glucose tolerance test (total and incremental area under the curve)

Citrate Synthase Activity (mitochondrial citrate synthase activity in each muscle sample in an immunocapture based manner)Change after 6 weeks

Skeletal muscle (vastus lateralis). Citrate Synthase Activity Assay Kit.

Fasting plasma triglyceride concentrationsBasal Concentrations - (change after 6 weeks)

Fasting plasma triglyceride concentrations (mmol/L)

Fasting plasma total cholesterol concentrationsBasal Concentrations - (change after 6 weeks)

Fasting plasma total cholesterol concentrations (mmol/L)

Fasting plasma non-esterified fatty acid concentrationsBasal Concentrations - (change after 6 weeks)

Fasting plasma non-esterified fatty acid concentrations (mmol/L)

Waist to hip ratioChange after 6 weeks

Waist circumference (cm) divided by hip circumference (cm)

Protein content of mitochondrial respiratory chain proteinsChange after 6 weeks. For each participant the protein content will be presented as the fold change from baseline (arbitrary units).

Skeletal muscle (vastus lateralis). Complex I, Complex II, Complex III, Complex IV.

Resting metabolic rate (RMR)Change after 6 weeks

Assessed via indirect calirometry

Adipose Tissue Insulin Resistance Index (Adipo-IR)Change after 6 weeks

Response to oral glucose tolerance test (total and incremental area under the curve)

Protein content of carnitine palmitoyltransferase I (CPT-1)Change after 6 weeks. For each participant the protein content will be presented as the fold change from baseline (arbitrary units)

Skeletal muscle (vastus lateralis)

Protein content of cluster of differentiation 36 (CD36)Change after 6 weeks. For each participant the protein content will be presented as the fold change from baseline (arbitrary units)

Skeletal muscle (vastus lateralis)

Protein content (total and phosphorylated form) of AMP-activated protein kinase (AMPK)Change after 6 weeks. For each participant the protein content will be presented as the fold change from baseline (arbitrary units)

Skeletal muscle (vastus lateralis)

Whole-body carbohydrate utilisation during exerciseChange throughout complete training period (weeks 1 through to 6). Samples will be collected during every training session (three times weekly for six weeks)

Assessed via indirect calirometry during every exercise session (at ten minute intervals)

Homeostasis Model Assessment (HOMA2-IR)Change after 6 weeks

The Homeostasis Model Assessment (HOMA) estimate of steady state beta cell function (%B) and insulin sensitivity (%S). Derived from fasting plasma glucose and fasting plasma insulin concentrations.

Energy balanceChange after 6 weeks (during week 6 of intervention versus baseline monitoring)

Total energy expenditure minus total energy intake

Whole-body lipid utilisation during exerciseChange throughout complete training period (weeks 1 through to 6). Samples will be collected during every training session (three times weekly for six weeks)

Assessed via indirect calirometry during every exercise session (at ten minute intervals)

Fasting plasma glycerol concentrationsBasal Concentrations - (change after 6 weeks)

Fasting plasma glycerol concentrations (mmol/L)

Trial Locations

Locations (1)

Department for Health, University of Bath

🇬🇧

Bath, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath